| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.34 | 1e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.24 | 3e-10 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-10 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.2 | 4e-09 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.17 | 6e-08 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.26 | 2e-07 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.17 | 5e-07 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-07 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-06 |